The 90‐Day Survival Threshold: A Pivotal Determinant of Long‐Term Prognosis in HBV‐ACLF Patients – Insights from a Prospective Longitudinal Cohort Study
Advanced Science · 2024
DOI: 10.1002/advs.202304381 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Advanced Science, 2024. Verfasst von Lanlan Xiao und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical …. Hauptthemen laut MEDLINE: Acute-On-Chronic Liver Failure. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, National Science and Technology Major Special Project, Key Technologies Research and Development Program.
Abstract (Originalsprache)
This work aims to explore the long‐term prognosis of hepatitis B virus‐related acute‐on‐chronic liver failure (HBV‐ACLF). In this prospective study, eligible inpatients with HBV‐ACLF are enrolled and followed up from December 2012 to February 2023, for clinical events, laboratory tests at least every 6 months. Overall, the survival rates at 28 days, 90 days, 1 year, 5 years, and 8 years are 64.7%, 48.8%, 46.1%, 43.8%, and 42.2%, respectively. Among the 8‐year mortality and liver transplant cases, ACLF survivors (who survived over 90 days) accounted for 7.8% (9/115). Among 101 patients who survived for more than 90 days, 97.9% of patients achieve virologic response at 1 year. For HBeAg‐positive patients, the HBeAg seroconversion are 25.5%, 63.6%, and 76.9% at 1, 5, and 8 years, respectively. Alanine aminotransferase, aspartate aminotransferase, total bilirubin, INR, white blood cell count, and albumin levels gradually improve within the first year. Fibrosis biomarkers APRI, FIB‐4 and Chitinase‐3‐like protein 1 (CHI3L1) levels decreases within the first 5 years. The Cox proportional hazards regression reveal that high total bilirubin (HR = 1.008, p = 0.021) is the independent risk factor for 8‐year survival of ALCF survivors. The 90‐day period following of HBV‐ACLF represented a critical juncture for long‐term prognosis, revealing favorable outcomes beyond this timeframe.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Di…
ORCID-Profile: Xiaowei Xu
Förderung
- Fundamental Research Funds for the Central Universities
- National Science and Technology Major Special Project
- Key Technologies Research and Development Program
Zitieren
APA
Xiao, L., Chen, J., Zhao, S., Zhoudi, W., He, K., Qian, X., Zhang, F., Liu, Q., Li, T., Zhu, D., Wu, X., Pu, Z., Huang, J., Xie, Z., & Xu, X. (2024). The 90‐Day Survival Threshold: A Pivotal Determinant of Long‐Term Prognosis in HBV‐ACLF Patients – Insights from a Prospective Longitudinal Cohort Study. Advanced Science. https://doi.org/10.1002/advs.202304381
Vancouver
Xiao L, Chen J, Zhao S, Zhoudi W, He K, Qian X, et al. The 90‐Day Survival Threshold: A Pivotal Determinant of Long‐Term Prognosis in HBV‐ACLF Patients – Insights from a Prospective Longitudinal Cohort Study. Advanced Science. 2024. doi:10.1002/advs.202304381
BibTeX
@article{Xiao2024,
author = {Xiao, Lanlan and Chen, Jiajia and Zhao, Shuai and Zhoudi, Wenxin and He, Keting and Qian, Xiaohan and Zhang, Fen and Liu, Qiuhong and Li, Tan and Zhu, Danhua and Wu, Xiaoxin and Pu, Zhangya and Huang, Jianrong and Xie, Zhongyang and Xu, Xiaowei},
title = {The 90‐Day Survival Threshold: A Pivotal Determinant of Long‐Term Prognosis in HBV‐ACLF Patients – Insights from a Prospective Longitudinal Cohort Study},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202304381}
}
EUVIMED